Chakraborty, A. et al. 2014. Inhibition of CaMKII does not attenuate cardiac hypertrophy in mice with dysfunctional ryanodine receptor. PLoS One. 9(8), pe104338.
Cheng, J. et al. 2012. CaMKII inhibition in heart failure, beneficial, harmful, or both. Am J Physiol Heart Circ Physiol. 302(7), pp.H1454-65.
El-Armouche, A. et al. 2004. Ouabain treatment is associated with upregulation of phosphatase inhibitor-1 and Na+/Ca2+-exchanger and beta-adrenergic sensitization in rat hearts. Biochemical and Biophysical Research Communications. 318(1), pp.219-226.
Ferreira, J.C. et al. 2011. Angiotensin receptor blockade improves the net balance of cardiac Ca(2+) handling-related proteins in sympathetic hyperactivity-induced heart failure. Life Sci. 88(13-14), pp.578-85.
Grote-Wessels, S. et al. 2008. Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload. Cardiovascular Research. 79(3), pp.464-471.
Kreuzberg, U. et al. 2000. Single-channel activity and expression of atrial L-type Ca(2+) channels in patients with latent hyperthyroidism. Am J Physiol Heart Circ Physiol. 278(3), pp.H723-30.
Liu, S.B. et al. 2011. FRET-based direct detection of dynamic protein kinase A activity on the sarcoplasmic reticulum in cardiomyocytes. Biochemical and Biophysical Research Communications. 404(2), pp.581-586.
Moilanen, A.M. and yliopisto, O. 2012. Identification of Noval Drug Targets for the Treatment of Heart Failure. University of Oulu.
Pugh, S.D. et al. 2014. Caveolin Contributes to the Modulation of Basal and beta-Adrenoceptor Stimulated Function of the Adult Rat Ventricular Myocyte by Simvastatin: A Novel Pleiotropic Effect. Plos One. 9(9).
Rastogi, S. et al. 2011. Myocardial transfection with naked DNA plasmid encoding hepatocyte growth factor prevents the progression of heart failure in dogs. American Journal of Physiology-Heart and Circulatory Physiology. 300(4), pp.H1501-H1509.
Ribeiro, R.F. et al. 2010. Soybean oil increases SERCA2a expression and left ventricular contractility in rats without change in arterial blood pressure. Lipids in Health and Disease. 9.
Scharf, M. et al. 2013. Mitogen-activated protein kinase-activated protein kinases 2 and 3 regulate SERCA2a expression and fiber type composition to modulate skeletal muscle and cardiomyocyte function. Mol Cell Biol. 33(13), pp.2586-602.
Sichelschmidt, O.J. et al. 2003. Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity. Cardiovascular Research. 58(3), pp.602-610.
Song, L. et al. 2007. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. Journal of Clinical Investigation. 117(7), pp.1814-1823.
Stangherlin, A. et al. 2011. cGMP Signals Modulate cAMP Levels in a Compartment-Specific Manner to Regulate Catecholamine-Dependent Signaling in Cardiac Myocytes. Circulation Research. 108(8), pp.929-U110.
Thireau, J. et al. 2014. Beta-adrenergic blockade combined with subcutaneous B-type natriuretic peptide: a promising approach to reduce ventricular arrhythmia in heart failure? Heart. 100(11), pp.833-41.
Vanzelli, A.S. et al. 2013. Integrative Effect of Carvedilol and Aerobic Exercise Training Therapies on Improving Cardiac Contractility and Remodeling in Heart Failure Mice. Plos One. 8(5).
Vila-Petroff, M. et al. 2007. CaMKII inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion injury. Cardiovascular Research. 73(4), pp.689-698.
Yamada, M. et al. 2006. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. Faseb Journal. 20(8), pp.1197-+.
Zhang, R. et al. 2005. Calmodulin kinase II inhibition protects against structural heart disease. Nature Medicine. 11(4), pp.409-417.
Zhao, X.Y. et al. 2008. rAAV-asPLB transfer attenuates abnormal sarcoplasmic reticulum Ca2+-ATPase activity and cardiac dysfunction in rats with myocardial infarction. European Journal of Heart Failure. 10(1), pp.47-54.
Badrilla is a manufacturer of outstanding antibodies against cardiac proteins and phospho-proteins, and the manufacturer of leading kits for the study of protein S-palmitoylation.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.I agree